Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Vladonix iconVladonixSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Vladonix

Beginner tier: 10 mg, daily · 4w on / 12w off · community consensus

ImmuneResearch
Unknown half-life·Oral

Also known as: A-6, Peptide Complex A-6, Thymus Bioregulator A-6

In one open-label study of 42 patients, 78% saw their T-lymphocyte parameters return to normal after a single 30-day course. Vladonix is an oral thymus peptide bioregulator from the Khavinson line, containing peptide complex A-6 extracted from calf thymus tissue. The catch: zero PubMed-indexed studies exist under its own name, and the strongest longevity data [1] actually used injectable Thymalin plus Epithalamin. Community adoption is small but consistent, centered on users running 30-day oral courses two to three times per year for age-related immune support. No injections. No reconstitution. Just capsules with meals.

What Is Vladonix?

Seventy-eight percent of patients with impaired immunity had their T-lymphocyte counts normalize after 30 days of capsules. That single data point is the core of what Vladonix (peptide complex A-6, oral thymus bioregulator) has going for it.

Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Vladonix contains a mixture of low-molecular-weight peptides (under 10 kDa) extracted from the thymus glands of young calves. The peptides are short enough, two to four amino acids, that Khavinson's group argues they survive gastric digestion and get absorbed via peptide transporters in the gut. No independent pharmacokinetic study has confirmed that claim for Vladonix specifically.

The proposed mechanism is epigenetic. Short-chain peptides from the A-6 complex bind DNA promoter regions in thymic epithelial cells, modulating gene expression tied to T-cell differentiation. In the n=42 study (ages 34 to 65), CD3+ and CD4+ counts increased reliably, and the CD4+/CD8+ ratio returned to normal ranges. B-cell parameters changed less.

Here is the honest assessment: zero PubMed results exist for "vladonix" as of 2026. All clinical data comes from one research group. The landmark longevity study (n=266)[1] used injectable Thymalin plus Epithalamin, not oral Vladonix, so its mortality-reduction findings don't transfer directly. Community adoption sits under five Reddit threads; most users run it inside multi-bioregulator stacks alongside Endoluten and Ventfort rather than as a standalone.

How Vladonix Works

Vladonix delivers a mixture of short thymus-derived peptides (peptide complex A-6) that are proposed to reach target immune cells after oral absorption. The absorption theory rests on molecular size. Peptides of two to four amino acids are small enough to resist complete enzymatic breakdown in the gut and get transported via PEPT and LAT peptide transporters. No bridging pharmacokinetic study has confirmed this for Vladonix specifically.

Once absorbed, the peptides are proposed to bind specific DNA sequences in promoter regions of immune-related genes. This interaction occurs in thymic epithelial cells and T-lymphocyte precursors. The net effect, per Khavinson's bioregulation model, is modulation of transcription rather than alteration of the underlying DNA sequence.

The downstream biological activity is T-cell focused. The peptide complex activates T-lymphocyte maturation, regulates the balance between CD4+ T-helper and CD8+ T-suppressor cells, and normalizes immunological reactivity. It also promotes regeneration in thymic tissue that has undergone age-related involution. These changes persist beyond the active dosing period, consistent with an epigenetic rather than pharmacokinetic mechanism.

This mechanism overlaps with injectable Thymalin (the parent extract) and its synthetic dipeptide derivative Thymogen (L-Glu-L-Trp). Vladonix uses the oral route and contains a broader peptide fraction than either.

Vladonix Benefits

  • Vladonix benefits center on T-cell normalization and thymic immune support during aging.
  • T-lymphocyte normalization in 78% of subjects (n=42, ages 34 to 65) after a single 30-day oral course, with reliable increases in CD3+ and CD4+ counts and restoration of the CD4+/CD8+ ratio (Khavinson-affiliated clinical study).
  • Thymus gland support during age-related involution; the peptide complex targets thymic epithelial cells directly, proposing to restore cellular immunity without systemic immune overstimulation.
  • Oral capsule format requires no injections, no reconstitution, and no refrigeration during storage; this makes it the most accessible option in the thymic peptide category.
  • Effects persist for months after a 30-day course. Community members most commonly report reduced infection frequency in the 4 to 12 weeks following a course rather than during active dosing.
  • No reported side effects or drug dependence in clinical observations across two decades of use in Russian clinical practice.
  • Can be combined with other bioregulators (Endoluten, Ventfort, Cerluten) or used as the oral alternative to injectable Thymalin for users who want to avoid needles.

Vladonix: Science vs Community Consensus

Aligned
Scientific Evidence
Weak
Based on 6 key studies·Research only

A single open-label clinical study (n=42, ages 34–65) reported normalization of impaired immune parameters in 78% of subjects, with reliable increases in CD3+ and CD4+ T-lymphocyte counts and restoration of the CD4+/CD8+ ratio.

Dosing studied: 10–40 mg/day oral (1–4 × 10 mg capsules) for 30 days; NPCRIZ official: 1–2 capsules, 1–2 times daily with meals
Read the evidence (key study, limitations)

This study was conducted by Khavinson affiliates and has not been independently replicated. The landmark longevity study [1] used injectable Thymalin, not oral Vladonix, so its mortality-reduction findings cannot be directly attributed to this product. Zero PubMed results for "vladonix" as of 2026. Mechanistic support for oral absorption of ultra-short peptides via PEPT/LAT transporters exists in theory but has not been confirmed by bridging PK studies for Vladonix specifically.

Key Study

Khavinson-affiliated open-label study, n=42 patients with immune dysfunction (ages 34–65): 78% normalized T-lymphocyte parameters (CD3+, CD4+ counts and CD4+/CD8+ ratio) after a 30-day Vladonix course. No PMID: not indexed in PubMed. Summarized via Bioregulator Atlas and community reports. The nearest indexed landmark is PMID 14523363 (combined Thymalin + Epithalamin, injectable, n=266).

Limitations

Zero PubMed entries for "vladonix". All primary evidence from one research group (Khavinson Institute, St. Petersburg). No blinding, no randomization, no placebo control in the cited clinical study. Oral bioavailability unconfirmed: gastric peptide degradation not formally characterized for the A-6 complex. Half-life and PK parameters are estimated, not measured. No Western regulatory review. Vladimir Khavinson died in 2024, reducing likelihood of future primary trial data from originating group.

Community Experience
Weak
3.0/5
Based on <5 dedicated Reddit threads

Very niche compound discussed almost exclusively in Khavinson bioregulator communities (ProjectBioHacked, AnabolicMinds bioregulator threads, commercial blogs) rather than general peptide forums.

Community dosing: 20 mg/day oral (2 × 10 mg capsules, once daily) for 30 days: most common community dose; some run 2 caps twice daily (40 mg/day) for first course
Read the reports (what users report 4, common issues 5)

Reddit signal is effectively absent: fewer than 5 dedicated threads identifiable. Users typically run Vladonix as part of a multi-bioregulator stack alongside Endoluten and Ventfort rather than as a standalone. Reported benefits are modest and difficult to attribute: reduced infection frequency and improved energy, typically noticed in the post-course weeks rather than during dosing. Oral format is the primary draw over injectable alternatives.

What users report (4)
  • Reduced frequency of minor infections in the 1–3 months after a course: most consistently cited community benefit
  • Improved energy and general wellbeing reported post-course, attributed to immune normalization
  • Oral format: avoids injectable protocols entirely; major practical advantage over Thymalin
  • Effects described as persistent for months after a 30-day course without continued dosing
Common issues (5)
  • Russian supply chain: product ships from Russia; batch-to-batch consistency and cold chain integrity unverifiable for resold product
  • Oral bioavailability unproven: community accepts the ultra-short peptide absorption theory but no PK data supports it
  • Very low discussion volume: hard to calibrate real-world response rate; most reports are anecdotal
  • Evidence sourced exclusively from Khavinson group; community cannot independently verify claims
  • Cost: $55–$156 per pack (20 or 60 caps); a standard 30-day course (60 caps at 2/day) costs $129–$156
Science & Community Aligned

Both the single clinical study and community reports converge on immune support / T-cell normalization as the primary outcome, and both describe effects that persist well beyond the active dosing period. The gap is one of magnitude and confidence: the clinical study quantifies T-lymphocyte parameter normalization; community experience reports softer endpoints (fewer infections, improved energy). No divergence in mechanism or dosing expectation: mechanistically consistent, just weakly evidenced from both directions.

Vladonix Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner10 mgDaily
Moderate20 mg2x Daily
Aggressive20 mg2x Daily
Note:

Vladonix is an oral capsule. No vials, no bacteriostatic water, no syringes. Each capsule contains 10 mg of peptide complex A-6 with a total capsule weight around 215 mg including excipients.

The standard community protocol is 2 capsules (20 mg) daily with breakfast for 30 days. That burns through 60 capsules per course. A 60-cap pack runs $130 to $156 depending on the product. If you're running the upper range of the NPCRIZ protocol (2 caps twice daily, 40 mg/day), you'll need 120 capsules per course.

Take capsules with food. GI discomfort in the first few days is the most common complaint, and it almost always traces back to empty-stomach dosing.

The thing most beginners miss: you won't feel anything during the 30-day course. Community members consistently report that benefits (fewer colds, improved energy) show up 4 to 12 weeks after stopping. Evaluate a course by what happens in the months following, not during.

Cycling Protocol

On Period
4 weeks
Off Period
12 weeks

Standard bioregulator protocol: 1-2 capsules daily for 30 days, then repeat every 3-6 months. Some protocols use a 10-day intensive course for maintenance. Effects persist well beyond the active dosing period.

Calculate your Vladonix dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Vladonix Protocols by Goal

beginnerCommunity30 days on, 3–6 months off; repeat 2 times per year
Standard Preventive Course
Wk 30 days (4.3 weeks)
20 mg (2 × 10 mg capsules) · Daily · Oral

Expected: Gradual immune parameter normalization; clinical study observed T-lymphocyte improvements by day 15–30. Community reports reduced infection frequency in the 1–3 months post-course rather than during active dosing.

Monitor: No mandatory lab monitoring for standard preventive protocol. Optional: CD3+/CD4+/CD8+ lymphocyte panel before and 4–6 weeks after course to assess T-cell normalization: the primary proposed mechanism.

How to Use Vladonix

  1. 1
    Take 1 to 2 capsules (10 to 20 mg) with breakfast

    Swallow whole with water. Do not open or crush capsules.

  2. 2
    Step 2

    If running the upper protocol range, add a second dose of 1 to 2 capsules with lunch or dinner. Avoid evening dosing if you notice immune stimulation disrupting sleep.

  3. 3
    Continue daily for 30 consecutive days

    Do not skip days; the proposed mechanism is cumulative epigenetic modulation that requires consistent exposure.

  4. 4
    After completing the 30-day course, stop

    Do not continue indefinitely. The Khavinson protocol is specifically designed as pulsed courses.

  5. 5
    Wait 3 to 6 months before your next course

    Most community members repeat at 3 to 4 months. Some practitioners use a 10-day mini-course (20 capsules at 2 per day) as monthly maintenance between full courses.

  6. 6
    Step 6

    Store capsules at room temperature (15 to 25 degrees Celsius) in original packaging, away from moisture and direct sunlight. No refrigeration required.

  7. 7
    Step 7

    Optional monitoring: run a lymphocyte subpopulation panel (CD3+, CD4+, CD8+, CD4+/CD8+ ratio) before your first course and 4 to 6 weeks after completing it. Normal CD4+/CD8+ ratio is 1.5 to 2.5 in adults.

Alternative Routes

Injectable (Thymalin)

Thymalin: 10–30 mg IM/SC daily for 5–10 days per course; total course dose lower than oral Vladonix due to superior bioavailability via injectable route

Thymalin has a stronger evidence base (clinical studies indexed in PubMed: PMID 12577695 and PMID 14523363 involve Thymalin). The injectable route bypasses GI degradation, making oral bioavailability assumptions moot. However, Thymalin is not available as a commercial dietary supplement in US/EU markets: requires import or prescription in applicable jurisdictions. Vladonix oral capsules are the accessible consumer alternative.

Vladonix Stacking Protocols

Works With

Avoid

Thymalin

Injectable pharmaceutical-grade version of the same thymus peptide fraction (A-6). Stacking Vladonix (oral A-6) with Thymalin (injectable A-6) creates redundant thymic peptide exposure. Choose one route; do not combine.

Thymulin

Thymulin is an endogenous thymic nonapeptide that also targets T-cell maturation. Mechanistic overlap with Vladonix's T-cell stimulation pathway. No combination study exists; concurrent use may cause excessive immune stimulation without additional benefit.

Thymosin Alpha-1

Both Vladonix and Thymosin Alpha-1 stimulate T-lymphocyte maturation and immune activation. Combining two immune-stimulating thymic agents risks excessive T-cell activation, particularly in individuals with borderline autoimmune conditions. Medical supervision required if combining.

Immunosuppressants (tacrolimus, cyclosporine, mycophenolate)

Vladonix stimulates T-cell proliferation and maturation: directly opposing the mechanism of immunosuppressant drugs. Concurrent use could counteract transplant rejection prevention or autoimmune management. Contraindicated in organ transplant recipients.

Do not combine

Estimated Cost

Brand Price
20-cap pack: ~$55; 60-cap pack: $129.99–$156. Standard 30-day course at 2 caps/day = 60 caps = $130–$156. Maintenance 10-day course at 2 caps/day = 20 caps = ~$55.

Pricing updated 2026-04-09

Vladonix Side Effects

The most important safety concern with Vladonix is immunostimulation in the wrong patient. Anyone with an active autoimmune condition, anyone taking immunosuppressant medications (tacrolimus, cyclosporine, mycophenolate), and organ transplant recipients should not take this product. T-cell stimulation directly opposes the mechanism of anti-rejection drugs. That interaction is not theoretical; it is pharmacologically predictable.

The second concern is the evidence gap. No controlled safety trial has been conducted. The total human safety data comes from one unblinded, unrandomized, open-label study of 42 patients (ages 34 to 65), conducted by the same group that developed the product. In that study, no adverse events were recorded. That is reassuring but far from complete.

Reported side effects in clinical use:

Published literature: none reported. Zero adverse events in the n=42 clinical study. No toxicity, no allergic reactions, no drug dependence across two decades of clinical observation in Russian practice.

Community reports: occasional mild GI discomfort (bloating, mild nausea) in the first one to three days when capsules are taken without food. This resolves by taking Vladonix with a full meal. The 40 mg/day dose (4 capsules per day) is more likely to cause GI adjustment than the standard 20 mg/day.

Bovine-derived product warning: Vladonix contains peptides extracted from calf thymus tissue. Individuals with known allergies to bovine-derived biological products should not use it. Prion risk is considered lower than for CNS-derived extracts (such as Cerluten or Cortexin) because thymus tissue carries lower prion burden than neural tissue; however, independent prion testing has not been published for Vladonix.

Supply chain risk: legitimate Vladonix is manufactured by NPCRIZ in St. Petersburg. Counterfeit Khavinson bioregulators exist in the market. Batch-to-batch consistency and cold chain integrity cannot be verified for resold product.

Pregnancy and breastfeeding: no safety data exists for these populations. Do not use.

Children under 18: not studied. Not recommended.

When to stop and see a doctor: any sign of allergic reaction (rash, urticaria, difficulty breathing), fever or signs of immune overactivation (unexpected lymphadenopathy, joint pain), or any new autoimmune symptoms.

Common Issues & Solutions

No noticeable effects during the 30-day course: Per the Khavinson bioregulation model, effects are epigenetic and cumulative: most users report reduced infection frequency and improved energy in the 4–12 weeks after the course ends, not during it. Confirm product authenticity; counterfeit Khavinson bioregulators exist.

Autoimmune concern: Vladonix is immune-stimulating (T-cell activation). Despite some marketing aimed at autoimmune patients, individuals with active autoimmune disease or on immunosuppressant therapy should not use it without direct physician oversight.

Supply chain and authenticity issues: Legitimate Vladonix is manufactured by NPCRIZ (St. Petersburg). Product ships from Russia. Verify product displays the A-6 / Khavinson Institute designation. Cold chain integrity cannot be confirmed for international shipments.

Oral bioavailability uncertainty: If questioning whether oral Vladonix is active, consider that injectable Thymalin (same peptide fraction, different route) has a stronger evidence base. Switch to Thymalin under medical supervision if oral bioavailability is a concern.

GI discomfort: Take with a full meal (not on an empty stomach). The 40 mg/day dose (4 capsules/day) is more likely to cause GI adjustment than the standard 20 mg/day. Reduce to 1 capsule/meal if needed.

Ask AI about this page

Ask AI for a second opinion on Vladonix dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no safety data in these populations
  • Known allergy to bovine-derived biological products
  • Active autoimmune conditions requiring immunosuppressive therapy
  • Organ transplant recipients on anti-rejection medications
  • Children under 18: not studied in pediatric populations

Drug Interactions

  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate): Vladonix may counteract immunosuppressive effects by stimulating T-cell activity
  • Other thymic peptides (Thymosin Alpha 1, Thymalin, Thymogen): overlapping mechanisms; avoid concurrent use without medical guidance
  • Corticosteroids: high-dose steroids may blunt the immunostimulatory effects of Vladonix
  • Vaccines: timing may need adjustment; immune modulation could alter the response to vaccination

Product Quality

Recommended Monitoring

TestWhenTarget
Lymphocyte subpopulation panel (CD3+, CD4+, CD8+, CD4+/CD8+ ratio)Before first course and 4–6 weeks after completing the 30-day courseCD4+/CD8+ ratio: normal adult range 1.5–2.5; CD4+ count: 500–1500 cells/µL (lab-specific norms vary)
Natural killer (NK) cell activityOptional; before first course if immune compromisedNot listed
Lymphocyte subpopulation panel (CD3+, CD4+, CD8+, CD4+/CD8+ ratio)

The primary proposed mechanism and the endpoint measured in the Khavinson n=42 study. Most direct biomarker to assess T-cell normalization. Useful for tracking response across courses.

Natural killer (NK) cell activity

Thymic peptides can also influence innate immune components. NK cell activity may provide an additional data point on immune restoration beyond T-cell subpopulation metrics.

Vladonix Before and After

Days 1-7

Course initiation. No noticeable changes expected. Peptides begin interacting with immune cell gene expression. Establish consistent daily dosing with meals.

Days 8-15

Early immune modulation underway. Some users report improved energy and fewer minor symptoms. T-cell precursor differentiation may be accelerating at the cellular level.

Days 16-30

Clinical studies showed measurable improvements in CD3+, CD4+ counts and CD4/CD8 ratios by this point. 78% of patients experienced normalized immune parameters. Complete the full 30-day course.

Weeks 5-12
post-course

Immune improvements continue to develop after the course ends. Reduced frequency of acute respiratory infections reported in observational data. Benefits persist without continued dosing.

Months 3-6
maintenance

Sustained immune benefits from a single course. Next course typically administered at the 3-6 month mark depending on individual needs and practitioner guidance.

What to Expect

Days 1 to 7: Nothing happens that you can feel. The short-chain peptides from the A-6 complex are proposed to begin interacting with DNA promoter regions in thymic epithelial cells and T-lymphocyte precursors at the molecular level. Occasional mild bloating in the first few days if you skip meals before dosing. Take capsules with food and this resolves.

Days 8 to 15: Early immune modulation may be underway at the cellular level. The n=42 clinical study reported measurable CD3+ and CD4+ improvements by mid-course in responsive patients. Some community users note improved energy or a vague sense of improved wellbeing. Most users report nothing specific at this stage. That is normal.

Days 16 to 30: This is when the clinical study measured its primary outcomes. T-lymphocyte normalization (CD3+, CD4+, CD4+/CD8+ ratio) appeared by end-of-course in 78% of subjects with immune dysfunction. Finish the full 30 days. Most community users still report minimal subjective effects during active dosing; the benefit is cumulative and shows up later.

Weeks 5 to 12 (post-course): The best window for noticing benefits, according to community reports. Reduced frequency of colds and respiratory infections is the most commonly cited outcome. Improved energy levels come second. The proposed explanation is that epigenetic changes in thymic tissue continue to produce downstream T-cell effects after dosing stops.

Months 3 to 6: Time to evaluate whether another course is warranted. The NPCRIZ protocol specifies repeat at 3 to 6 month intervals. Most community members who run ongoing protocols repeat at 3 to 4 months. Elderly users focused on geroprotection tend to run two full 30-day courses per year. Some practitioners insert a 10-day mini-course (20 capsules) as monthly maintenance between full courses.

Detailed Timeline: Science vs Community

Days 1–7
Science

Short-chain peptides from A-6 complex begin interacting with DNA promoter regions in thymic epithelial cells and T-lymphocyte precursors. No measurable immune parameter changes expected in week 1.

Community

No noticeable changes. Standard experience. Occasional mild GI adjustment (bloating) in days 1–3 if taken without food.

Days 8–15
Science

T-lymphocyte precursor differentiation and maturation proposed to be underway. The clinical study reported measurable CD3+ and CD4+ improvements by mid-course in responsive patients.

Community

Some users note improved energy or sense of wellbeing. No dramatic changes expected. Most users report nothing specific at this stage.

Days 16–30
Science

The Khavinson-affiliated n=42 study found measurable T-lymphocyte normalization (CD3+, CD4+, CD4+/CD8+ ratio) by end of a 30-day course in 78% of subjects with immune dysfunction. Complete the full 30-day course.

Community

Still minimal subjective effects during active dosing for most users. Benefit is cumulative and typically noticed in the weeks after stopping.

Weeks 5–12 (post-course)
Science

The epigenetic mechanism proposed by Khavinson predicts lasting gene expression changes in thymic tissue that persist beyond the active dosing period. Effects should continue to develop 4–8 weeks post-course.

Community

Most commonly cited as the best window for noticing benefits: reduced frequency of colds/respiratory infections, improved energy. Most community members evaluate a course by outcomes in this 6–10 week window.

Months 3–6
Science

NPCRIZ protocol specifies repeat at 3–6 month intervals. No comparative data on optimal inter-course interval. Some practitioners use a 10-day mini-course (20 caps) as monthly maintenance between full courses.

Community

Most users repeat at 3–4 months if benefits have faded. Elderly users oriented toward broad geroprotection may run 2 full 30-day courses per year as their primary anti-aging protocol component.

Pharmacokinetics

Half-Life
N/A
Bioavailability
Oral: unknown; likely low for individual peptide fragments
Tmax
Unknown: no formal PK studies
Data Confidence
low

Source: No Vladonix-specific PK data published, so no half-life is given. Oral bioregulator peptides are rapidly degraded.

Who Should Consider Vladonix

  • Adults over 50 experiencing age-related immune decline (immunosenescence)
  • Individuals with frequent or recurrent infections seeking immune support
  • Those who prefer oral peptides over injectable protocols
  • Post-illness recovery where immune restoration is desired
  • People interested in Khavinson bioregulator protocols for longevity

Related Peptides

What Changed for Vladonix

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Peptides of Pineal Gland and Thymus Prolong Human Life (Neuroendocrinol Lett 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store at room temperature in original packaging, away from moisture and direct sunlight
After Reconstitution
N/A: oral capsule, no reconstitution needed
Temperature
Room temperature (15-25°C / 59-77°F)

Frequently Asked Questions

No. Thymalin is an injectable pharmaceutical-grade peptide extract with clinical data including Khavinson's longevity RCTs (PMID 14523363) showing mortality reduction in elderly patients. Vladonix is an oral capsule containing the same peptide fraction (A-6) designed for supplement use. No formal bioavailability study demonstrates that oral Vladonix achieves equivalent blood levels or effects compared to injectable Thymalin.

Each capsule contains 10 mg of peptide complex A-6 (total capsule weight about 215 mg with excipients). The NPCRIZ protocol is 1-2 capsules, 1-2 times daily with meals, for 30 days, meaning 10-40 mg/day. Repeat every 3-6 months.

Khavinson's group argues the ultra-short peptide chains (2-4 amino acids) are small enough to resist enzymatic breakdown and get absorbed via peptide transporters. A 2023 publication references this mechanism. However, no independent PK study has measured plasma levels of Vladonix peptides after oral dosing. It's an assumption based on molecular size, not measured bioavailability.

The proposed mechanism is epigenetic: the short peptides bind to DNA promoter regions in T-cell precursors and thymic epithelial cells, modulating gene expression in ways that persist beyond the drug's presence. Consistent with Khavinson's broader bioregulation theory, but no mechanistic human study has directly confirmed this for Vladonix. It's inferred from clinical observation.

Vladonix is commonly stacked with other Khavinson bioregulators (Ventfort, Endoluten, Cerluten) in the longevity community with no reported issues. Since Vladonix is immune-activating (T-cell stimulation), combining it with immunosuppressants or other immune-active peptides needs medical supervision. BPC-157 and TB-500 target different pathways (tissue repair vs immune maturation) and are sometimes used concurrently without problems, though no formal combination data exists.